The Central Drugs Standard Control Organization (CDSCO) has taken action against Pres Vu eye drops, a product that claimed to replace reading glasses. The drug regulator has suspended the manufacturing license of the company producing the eye drops, citing concerns about its safety and efficacy.
The CDSCO’s decision comes after receiving numerous complaints and concerns regarding the product’s claims. While the exact nature of the complaints remains undisclosed, the regulator has indicated that the eye drops may not be safe for use and could potentially cause adverse side effects.
Pres Vu, which gained popularity due to its promise of eliminating the need for reading glasses, had been marketed as a solution for age-related vision problems. However, the CDSCO’s investigation has found that the product’s claims were not supported by adequate scientific evidence.
Pres Vu’s Response
Entod Pharmaceuticals has yet to provide a satisfactory response to the queries raised by the DCGI. The company attempted to justify its claims by stating that there are currently no other eye drops approved for the treatment of presbyopia in India. However, the regulator emphasized that this does not validate the misleading marketing of PresVu2.
The suspension of the manufacturing license means that the production and sale of Pres Vu eye drops have been halted. The CDSCO has also urged consumers who have already purchased the product to discontinue its use and consult with a healthcare professional if they experience any adverse symptoms.
This incident serves as a reminder of the importance of exercising caution when considering over-the-counter products, especially those making extraordinary claims. It is always advisable to consult with a healthcare professional before using any new medication or treatment.
